Screener
Nurix Therapeutics, Inc. NRIX Bexobrutideg (NX-5948) — R&D
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
| Line item | Three Months Ended May 31, 2026 | Three Months Ended May 31, 2025 | Six Months Ended May 31, 2026 | Six Months Ended May 31, 2025 |
|---|---|---|---|---|
| External clinical development expenses: | ||||
| Bexobrutideg (NX-5948) | $28,192 | $18,558 | $52,166 | $34,278 |
| Zelebrudomide (NX-2127) | 1,167 | 1,559 | 3,073 | 2,665 |
| NX-1607 | 1,738 | 2,332 | 2,926 | 4,292 |
| Internal research and development expenses | 56,556 | 55,647 | 113,624 | 106,524 |
| Total research and development expenses | $87,653 | $78,096 | $171,789 | $147,759 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Nurix Therapeutics, Inc.'s bexobrutideg (NX-5948) — R&D?
- Nurix Therapeutics, Inc. (NRIX) reported bexobrutideg (NX-5948) — R&D of $28.19M in Q1 2026.
- How has Nurix Therapeutics, Inc.'s bexobrutideg (NX-5948) — R&D changed year-over-year?
- Nurix Therapeutics, Inc.'s bexobrutideg (NX-5948) — R&D increased by 51.9% year-over-year, from $18.56M to $28.19M.
- What does bexobrutideg (NX-5948) — R&D mean?
- This metric represents the total direct operating expenses allocated to the research, clinical development, and pre-commercialization activities for a specific therapeutic candidate. It captures the investment intensity required to advance a drug through clinical trials and regulatory milestones. Monitoring this spend provides insight into the company's capital allocation strategy and the prioritization of its pipeline assets.
Ask your AI about Nurix Therapeutics, Inc.'s bexobrutideg (nx-5948) — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude